English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Significance This work addresses a key question in the field of liver receptor homolog-1 (LRH-1) pathophysiology in colorectal cancer (CRC)—namely, does LRH-1 contribute exclusively to tumorigenesis, or does LRH-1 also drive established CRC tumor growth? These two models have widely different implications for pharmaceutical targeting in CRC. To our knowledge, our work is the first to demonstrate that silencing of LRH-1 in established human CRC cell lines impairs proliferation though G0/G1 phase prolongation. Our microarray gene expression analysis shows that loss of LRH-1 expression yields alterations in diverse cellular pathways consistent with the critical role of LRH-1 in CRC. Taken together, our study suggests that a subset of CRC patients could benefit from selective antagonism of LRH-1.

Silencing LRH-1 in colon cancer cell lines impairs proliferation and alters gene expression programs